Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05652530 | Clinical Study of the Safety and Efficacy of BCMA CAR-NK | unknown | Early Phase 1 | 19 | Shenzhen Pregene Biopharma Co., Ltd.INDUSTRY | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05651100 | Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 50 | Kecellitics Biotech Company LtdINDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05651191 | To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL | unknown | Early Phase 1 | 9 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05639179 | Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | unknown | Phase 1 / Phase 2 | 30 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT02752815 | Reduced Chemotherapy in Low Risk DLBCL | unknown | Phase 4 | 290 | Ruijin HospitalOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT01811368 | Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | unknown | Phase 2 | 20 | Joseph TuscanoOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05266768 | Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002# | unknown | Phase 1 | 36 | Chunrui LiOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05291390 | Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 200 | Armaceutica, Inc.INDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05619861 | CAR-T Cells in the Treatment of Malignant Hematological Tumors | unknown | N/A | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05415098 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | unknown | Phase 1 | 90 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Nov 16, 2022 | clinicaltrials |
| NCT03664297 | Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor | unknown | Phase 1 | 86 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05254821 | Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients | unknown | — | 130 | Federico II UniversityOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05559008 | A Umbrella Study in R/R PTCL Guided by Molecular Subtypes | unknown | Phase 1 / Phase 2 | 116 | Ruijin HospitalOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT04481815 | Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | unknown | Phase 2 | 240 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05577884 | Ultra-low-dose Whole-body CT Using AI-based CT Reconstruction in Patients With Multiple Myeloma | unknown | — | 30 | Seoul National University HospitalOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT03460522 | Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL | unknown | Phase 2 | 65 | Nicola GoekbugetOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05016778 | A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma | unknown | Early Phase 1 | 15 | Zhejiang UniversityOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT05565898 | PET/CT Vs Bone Marrow Biopsy in Exclusion of Bone Marrow Infiltration for Initial Staging of Lymphoma | unknown | — | 100 | Assiut UniversityOTHER | 0 | Nov 1, 2022 | clinicaltrials |
| NCT05600959 | Sensitivity and Specificity of Cytokines in the Diagnosis of Lymphoma-associated HLH | unknown | — | 60 | Beijing Friendship HospitalOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT05598268 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | unknown | Phase 1 / Phase 2 | 74 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT02098512 | Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients | unknown | Phase 1 / Phase 2 | 20 | New York Medical CollegeOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05479136 | 18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy(DRARCH) | unknown | Phase 3 | 30 | Nicole HillOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05596097 | Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission | unknown | Phase 2 | 15 | LanZhou UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05596266 | CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 20 | Xuanwu Hospital, BeijingOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05135858 | Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma(METHOGLU) | unknown | Phase 1 | 18 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT05592470 | commd7 Gene Expression in ALL | unknown | — | 102 | Assiut UniversityOTHER | 0 | Oct 24, 2022 | clinicaltrials |
| NCT05578378 | Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL | unknown | Phase 2 / Phase 3 | 32 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05578625 | ctDNA Methylation Sequencing for Myeloma | unknown | — | 66 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT03318770 | Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | unknown | — | 60 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04118868 | Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma. | unknown | Phase 1 | 10 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04438044 | A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL | unknown | Phase 2 | 61 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05575973 | Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma | unknown | Phase 2 | 55 | Jianfeng ZhouOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05569057 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma | unknown | Phase 1 | 100 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 7, 2022 | clinicaltrials |
| NCT05561049 | Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma | unknown | — | 120 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Sep 30, 2022 | clinicaltrials |
| NCT04033627 | TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia | unknown | N/A | 30 | Shanghai Children's Medical CenterOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05367856 | Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma | unknown | Phase 2 | 23 | Ruijin HospitalOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05559450 | Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL | unknown | Phase 2 | 80 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05557903 | Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL | unknown | Phase 1 | 71 | Lanzhou Institute of Biological Products Co., LtdINDUSTRY | 1 | Sep 28, 2022 | clinicaltrials |
| NCT04684472 | Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies | unknown | Phase 1 | 18 | Liqun ZouOTHER | 1 | Sep 26, 2022 | clinicaltrials |
| NCT05549284 | Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)(RMO) | unknown | Phase 2 | 36 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT05549973 | Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 | 32 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT05548686 | Benefits of Adapted Physical Activity for Chronic Osteoarticular Pain in Patients With Multiple Myeloma(ALGOMYELOMOV) | unknown | N/A | 15 | University Hospital, CaenOTHER | 0 | Sep 21, 2022 | clinicaltrials |
| NCT03280160 | Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab | unknown | Phase 2 | 84 | PETHEMA FoundationOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT05543070 | Low-dose Radiotherapy in iNHL | unknown | Phase 2 | 73 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT03891355 | Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL(FIL_KLIMT) | unknown | Phase 2 | 16 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05536700 | Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma | unknown | — | 67 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT04277845 | Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma(KMM1910) | unknown | Phase 2 | 49 | Samsung Medical CenterOTHER | 1 | Sep 9, 2022 | clinicaltrials |
| NCT04688853 | A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients | unknown | Phase 1 | 26 | Gadeta B.V.INDUSTRY | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05532761 | Multidimensional Assessment of Quality of Life, Social and Professional Life and Care Utilization in Patients With Diffuse Large Cell B-cell Lymphoma Treated With CAR-T Cells(QUALITOP CAR-T) | unknown | — | 30 | Hospices Civils de LyonOTHER | 1 | Sep 8, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Dec 15, 2022source: clinicaltrials